Date: 2015-06-15
Type of information: Initiation of preclinical development
phase: preclinical
Announcement: initiation of preclinical development
Company: Tikcro Technologies (Israel)
Product: immune checkpoint antibodies
Action
mechanism: immune checkpoint inhibitor
Disease:
Therapeutic area: Cancer - Oncology
Country:
Trial details:
Latest
news: * On June 15, 2015, Tikcro Technologies announced that it will proceed with a pre-clinical plan for the generation and verification of new antibodies targeting the modulation of CTLA4 and PD1 cancer checkpoints. Based on a novel approach, it is expected that such new antibodies will be generated and validated throughout 2015. These antibodies are expected to have greater specificity and binding qualities over existing antibodies. CTLA4 and PD1 are acknowledged as key elements for harnessing a patient\'s own immune system in cancer treatments. Antibodies targeting these checkpoints were approved for clinical use. Interim clinical results show strong synergistic benefit for a combination treatment of such antibodies.
